Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAAE vs Spironolactone for Idiopathic Hyperaldosteronism
NCT07328230Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, open-label trial in idiopathic hyperaldosteronism (IHA) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Change of 24-h mean systolic blood pressure at 6 months. Started Aug 2022; status: recruiting.
02
Conditions
idiopathic hyperaldosteronism (IHA)
Beyond the preview
Go deeper on NCT07328230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328230.